NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
These approvals mark significant progress for Venus Remedies in expanding its market presence
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
These regulatory approvals signify a significant milestone for Venus Remedies Limited
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Supply readiness follows months of manufacturing to ensure timely and ample supply
This request for withdrawal of the two dossiers was made after necessary consultations and receiving guidance from EMA
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
Subscribe To Our Newsletter & Stay Updated
